Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Current HIV/AIDS Reports
Published in: Current HIV/AIDS Reports 3/2014

01-09-2014 | Complications of Antiretroviral Therapy (JM Kilby, Section Editor)

Drug Interactions and Antiretroviral Drug Monitoring

Authors: Matthew Foy, C. John Sperati, Gregory M. Lucas, Michelle M. Estrella

Published in: Current HIV/AIDS Reports | Issue 3/2014

Login to get access

Abstract

Owing to the improved longevity afforded by combination antiretroviral therapy (cART), HIV-infected individuals are developing several non-AIDS-related comorbid conditions. Consequently, medical management of the HIV-infected population is increasingly complex, with a growing list of potential drug-drug interactions (DDIs). This article reviews some of the most relevant and emerging potential interactions between antiretroviral medications and other agents. The most common DDIs are those involving protease inhibitors or non-nucleoside reverse transcriptase inhibitors, which alter the cytochrome P450 enzyme system and/or drug transporters such as p-glycoprotein. Of note are the new agents for the treatment of chronic hepatitis C virus infection. These new classes of drugs and others drugs that are increasingly used in this patient population represent a significant challenge with regard to achieving the goals of effective HIV suppression and minimization of drug-related toxicities. Awareness of DDIs and a multidisciplinary approach are imperative in reaching these goals.
Literature
1.
Palella Jr FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27–34.PubMedCrossRef
2.
3.
Goulet JL, Fultz SL, Rimland D, et al. Aging and infectious diseases: do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45:1593–601.PubMedCentralPubMedCrossRef
4.
Marzolini C, Elzi L, Gibbons S, et al. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010;15:413–23.PubMedCrossRef
5.
von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol. 1998;38:106–11.CrossRef
6.
Minuesa G, Huber-Ruano I, Pastor-Anglada M, Koepsell H, Clotet B, Martinez-Picado J. Drug uptake transporters in antiretroviral therapy. Pharmacol Ther. 2011;132:268–79.PubMedCrossRef
7.
Kim RB. Drug transporters in HIV Therapy. Top HIV Med. 2003;11:136–9.PubMed
8.
Belanger AS, Caron P, Harvey M, Zimmerman PA, Mehlotra RK, Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and an in vitro investigation of drug-drug interaction with zidovudine. Drug Metab Dispos. 2009;37:1793–6.PubMedCentralPubMedCrossRef
9.
Mano Y, Usui T, Kamimura H. Inhibitory potential of nonsteroidal anti-inflammatory drugs on UDP-glucuronosyltransferase 2B7 in human liver microsomes. Eur J Clin Pharmacol. 2007;63:211–6.PubMedCrossRef
10.•
Jimenez-Nacher I, Alvarez E, Morello J, Rodriguez-Novoa S, de Andres S, Soriano V. Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. Expert Opin Drug Metab Toxicol. 2011;7:457–77. This paper comprehensively reviews potential DDIs among antiretroviral medications and other drugs and describes potential mechanisms for these DDIs.PubMedCrossRef
11.••
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at:http://​aidsinfo.​nih.​gov/​ContentFiles/​AdultandAdolesce​ntGL.​pdf. Accessed 5 Apr 2014. This panel report provides comprehensive guidelines for the antiretroviral treatment of HIV-infected patients, which are updated regularly by a panel of experts.It includes helpful tables for various DDIs.
12.
Jimenez-Nacher I, Garcia B, Barreiro P, et al. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother. 2008;62:816–22.PubMedCrossRef
13.
Baxi SM, Greenblatt RM, Bacchetti P, et al. Common clinical conditions—age, low BMI, ritonavir use, mild renal impairment—affect tenofovir pharmacokinetics in a large cohort of HIV-infected women. AIDS. 2014;28:59–66.PubMedCrossRef
14.
Pruvost A, Negredo E, Theodoro F, et al. Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir. Antimicrob Agents Chemother. 2009;53:1937–43.PubMedCentralPubMedCrossRef
15.
Kearney BP, Mathias A, Mittan A, Sayre J, Ebrahimi R, Cheng AK. Pharmacokinetics and safety of tenofovir disoproxil fumarate on coadministration with lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2006;43:278–83.PubMedCrossRef
16.
Izzedine H, Harris M, Perazella MA. The nephrotoxic effects of HAART. Nat Rev Nephrol. 2009;5:563–73.PubMedCrossRef
17.
Cihlar T, Ray AS, Laflamme G, et al. Molecular assessment of the potential for renal drug interactions between tenofovir and HIV protease inhibitors. Antivir Ther. 2007;12:267–72.PubMed
18.
Tong L, Phan TK, Robinson KL, et al. Effects of human immunodeficiency virus protease inhibitors on the intestinal absorption of tenofovir disoproxil fumarate in vitro. Antimicrob Agents Chemother. 2007;51:3498–504.PubMedCentralPubMedCrossRef
19.
Soriano V, Arasteh K, Migrone H, et al. Nevirapine vs atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther. 2011;16:339–48.PubMedCrossRef
20.
Lockman S, Hughes M, Sawe F, et al. Nevirapine- vs lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. PLoS Med. 2012;9:e1001236.PubMedCentralPubMedCrossRef
21.
Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C Virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis. 2002;34:831–7.PubMedCrossRef
22.
van der Helm JJ, Prins M, del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS. 2011;25:1083–91.PubMedCrossRef
23.
Brau N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol. 2006;44:47–55.PubMedCrossRef
24.
Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22:1979–91.PubMedCrossRef
25.•
Pawlotsky JM. New Hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology. 2014;146:1176–92. This review describes the new antiviral agents for the treatment of HCV, including those which are already FDA-approved and those which are still in development.
26.
Garg V, Kauffman RS, Beaumont M, van Heeswijk RP. Telaprevir: pharmacokinetics and drug interactions. Antivir Ther. 2012;17:1211–21.PubMedCrossRef
27.••
Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013;56:718–26. This paper showed the important interactions between the novel anti-HCV agent, boceprevir, and several RTV-boosted PIs.PubMedCrossRef
28.
29.•
Gutierrez-Valencia A, Ruiz-Valderas R, Torres-Cornejo A, et al. Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir. Clin Infect Dis. 2014;58:268–73. This paper provided evidence that supports the important role of RTV in the observed interactions between telaprevir and RTV-boosted atazanavir and likely other RTV-boosted PIs.PubMedCrossRef
30.
31.
32.
33.
Bifano M, Hwang C, Oosterhuis B, et al. Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir. Antivir Ther. 2013;18:931–40.PubMedCrossRef
34.
Seaberg EC, Munoz A, Lu M, et al. Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003. AIDS. 2005;19:953–60.PubMedCrossRef
35.
Medina-Torne S, Ganesan A, Barahona I, Crum-Cianflone NF. Hypertension is common among HIV-infected persons, but not associated with HAART. J Int Assoc Phys AIDS Care. 2012;11:20–5.CrossRef
36.
Baekken M, Os I, Sandvik L, Oektedalen O. Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy. J Hypertens. 2008;26:2126–33.PubMedCrossRef
37.
Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003;22:731–6.PubMedCrossRef
38.
Peyriere H, Eiden C, Macia JC, Reynes J. Antihypertensive drugs in patients treated with antiretrovirals. Ann Pharmacother. 2012;46:703–9.PubMedCrossRef
39.
Sica DA. Calcium channel blocker class heterogeneity: select aspects of pharmacokinetics and pharmacodynamics. J Clin Hypertens. 2005;7:21–6.CrossRef
40.
Siest G, Jeannesson E, Visvikis-Siest S. Enzymes and pharmacogenetics of cardiovascular drugs. Clin Chim Acta. 2007;381:26–31.PubMedCrossRef
41.
42.
Anderson AM, Chane T, Patel M, Chen S, Xue W, Easley KA. Warfarin therapy in the HIV medical home model: low rates of therapeutic anticoagulation despite adherence and differences in dosing based on specific antiretrovirals. AIDS Patient Care STDS. 2012;26:454–62.PubMedCentralPubMedCrossRef
43.
Egan G, Hughes CA, Ackman ML. Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother. 2014;48:734-40.
44.
Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013;76:455–66.PubMedCrossRef
45.
Hagihara K, Kazui M, Kurihara A, et al. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel. Drug Metab Dispos. 2009;37:2145–52.PubMedCrossRef
46.
Ancrenaz V, Deglon J, Samer C, et al. Pharmacokinetic interaction between prasugrel and ritonavir in healthy volunteers. Basic Clin Pharmacol Toxicol. 2013;112:132–7.PubMedCentralPubMedCrossRef
47.
Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs. 2013;73:1681–709.PubMedCrossRef
48.
49.
Chauvin B, Drouot S, Barrail-Tran A, Taburet AM. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. Clin Pharmacokinet. 2013;52:815–31.PubMedCrossRef
50.
Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613–27.PubMedCrossRef
51.
Aquilante CL, Kiser JJ, Anderson PL, et al. Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin. J Clin Pharmacol. 2012;52:1725–38.PubMedCrossRef
52.
Samineni D, Desai PB, Sallans L, Fichtenbaum CJ. Steady-state pharmacokinetic interactions of darunavir/ritonavir with lipid-lowering agent rosuvastatin. J Clin Pharmacol. 2012;52:922–31.PubMedCrossRef
53.
Aslangul E, Assoumou L, Bittar R, et al. Rosuvastatin vs pravastatin in dyslipidemic HIV-1-infected patients receiving protease inhibitors: a randomized trial. AIDS. 2010;24:77–83.PubMedCrossRef
54.
Custodio JM, Wang H, Hao J, et al. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin. J Clin Pharmacol. 2014;54:649–56.
55.
Hirano M, Maeda K, Shitara Y, Sugiyama Y. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos. 2006;34:1229–36.PubMedCrossRef
56.
Morgan RE, Campbell SE, Suehira K, Sponseller CA, Yu CY, Medlock MM. Effects of steady-state lopinavir/ritonavir on the pharmacokinetics of pitavastatin in healthy adult volunteers. J Acquir Immune Defic Syndr. 2012;60:158–64.PubMedCrossRef
57.
Sponseller CA. Pitavastatin 4 mg provides greater LDL-C reduction compared with pravastatin 40 mg over 12 weeks of treatment in HIV-infected adults with dyslipidemia. In: 20th Conference on Retroviruses & Opportunistic Infections: Atlanta, GA; 2013.
58.
59.
Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8:355–65.PubMedCrossRef
60.
Gathogo EN, Hamzah L, Hilton R, et al. Kidney transplantation in HIV-positive adults: the UK experience. Int J STD Aids. 2014;25:57–66.PubMedCrossRef
61.
Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol. 2007;2:374–84.PubMedCrossRef
62.
Teicher E, Vincent I, Bonhomme-Faivre L, et al. Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study. Clin Pharmacokinet. 2007;46:941–52.PubMedCrossRef
63.
Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation. 2005;80:13–7.PubMedCrossRef
64.
Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7:2816–20.PubMedCrossRef
65.
Jain AK, Venkataramanan R, Fridell JA, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. 2002;8:838–40.PubMedCrossRef
66.
Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet. 1998;34:429–55.PubMedCrossRef
67.
Sankatsing SU, Hoggard PG, Huitema AD, et al. Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools. Clin Pharmacokinet. 2004;43:823–32.PubMedCrossRef
68.
Margolis D, Heredia A, Gaywee J, Oldach D, Drusano G, Redfield R. Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. J Acquir Immune Defic Syndr. 1999;21:362–70.PubMedCrossRef
69.
Margolis DM, Kewn S, Coull JJ, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. J Acquir Immune Defic Syndr. 2002;31:45–9.PubMedCrossRef
70.
Trkulja V, Lalic Z, Nad-Skegro S, et al. Effect of cyclosporine on steady-state pharmacokinetics of MPA in renal transplant recipients is not affected by the MPA formulation: analysis based on therapeutic drug monitoring data. Ther Drug Monit. 2014. doi:10.​1097/​FTD.​0000000000000052​.
71.
Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007;35:1657–63.PubMedCrossRef
72.
Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant. 2009;9:1946–52.PubMedCrossRef
73.
McColl DJ, Chen X. Strand transfer inhibitors of HIV-1 integrase: bringing in a new era of antiretroviral therapy. Antiviral Res. 2010;85:101–18.PubMedCrossRef
74.
Kiser JJ, Bumpass JB, Meditz AL, et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother. 2010;54:4999–5003.PubMedCentralPubMedCrossRef
75.
Patel P, Song I, Borland J, et al. Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers. J Antimicrob Chemother. 2011;66:1567–72.PubMedCrossRef
76.•
Ramanathan S, Mathias A, Wei X, et al. Pharmacokinetics of once-daily boosted elvitegravir when administered in combination with acid-reducing agents. J Acquir Immune Defic Syndr. 2013;64:45–50. This study demonstrated that boosted elvitegravirinteracts with antacids but notwith H 2 R-blockers or PPis. Its interaction with antacid is likely due to chelation of divalent ions.PubMedCrossRef
77.
Wang X, Boffito M, Zhang J, et al. Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients. AIDS Patient Care STDS. 2011;25:509–15.PubMedCentralPubMedCrossRef
78.
McCabe SM, Smith PF, Ma Q, Morse GD. Drug interactions between proton pump inhibitors and antiretroviral drugs. Expert Opin Drug Metab Toxicol. 2007;3:197–207.PubMedCrossRef
79.
Ramanathan S, Mathias AA, German P, Kearney BP. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir. Clin Pharmacokinet. 2011;50:229–44.PubMedCrossRef
80.
Iwamoto M, Wenning LA, Nguyen BY, et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis. 2009;48:489–92.PubMedCrossRef
81.
Pau AK. Clinical management of drug interaction with antiretroviral agents. Curr Opin HIV AIDS. 2008;3:319–24.PubMedCrossRef
82.••
Krakower D, Kwan CK, Yassa DS, Colvin RA. iAIDS: HIV-related internet resources for the practicing clinician. Clin Infect Dis. 2010;51:813–22. This article evaluates several online resources, which are clinically useful in the management of potential DDIs among HIV-infected patients.PubMedCrossRef
83.
Haas DW. Can responses to antiretroviral therapy be improved by therapeutic drug monitoring? Clin Infect Dis. 2006;42:1197–9.PubMedCrossRef
84.
Nettles RE, Kieffer TL, Parsons T, et al. Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring. Clin Infect Dis. 2006;42:1189–96.PubMedCrossRef
85.
Schoenenberger JA, Aragones AM, Cano SM, et al. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems. Ther Drug Monit. 2013;35:71–7.PubMedCrossRef
Metadata
Title
Drug Interactions and Antiretroviral Drug Monitoring
Authors
Matthew Foy
C. John Sperati
Gregory M. Lucas
Michelle M. Estrella
Publication date
01-09-2014
Publisher
Springer US
Published in
Current HIV/AIDS Reports / Issue 3/2014
Print ISSN: 1548-3568
Electronic ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-014-0212-1

Other articles of this Issue 3/2014

Current HIV/AIDS Reports 3/2014 Go to the issue

Complications of Antiretroviral Therapy (JM Kilby, Section Editor)

Immune Reconstitution Disorders in Patients With HIV Infection: From Pathogenesis to Prevention and Treatment

Complications of Antiretroviral Therapy (JM Kilby, Section Editor)

Bone Alterations Associated with HIV

Co-infections and Comorbidity (CM Wyatt and K Sigel, Section Editors)

Functional Impairment, Disability, and Frailty in Adults Aging with HIV-Infection

Co-infections and Comorbidity (CM Wyatt and K Sigel, Section Editors)

Depression and Adherence to Antiretroviral Therapy in Low-, Middle- and High-Income Countries: A Systematic Review and Meta-Analysis

Central Nervous System and Cognition (I Grant, Section Editor)

Chronic Inflammation and the Role for Cofactors (Hepatitis C, Drug Abuse, Antiretroviral Drug Toxicity, Aging) in HAND Persistence

Co-infections and Comorbidity (CM Wyatt and K Sigel, Section Editors)

Incarceration of People Living with HIV/AIDS: Implications for Treatment-as-Prevention

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits